For the Inventor, By the Inventor

Enter assignee name

Victoria, Australia

Amrad Corporation Limited

USPTO Granted Patents = 33

CIPO Patents = 2

Trademarks = 1

Forward Citations = 447

Loading Chart...

Loading Chart...

48 inventors (with patents filed for the assignee):

Nicholas Martin Gough (13 out of 15 patents)

Donald Metcalf (12 out of 21 patents)

Nicos Anthony Nicola (10 out of 23 patents)

4. Richard John Simpson (8 out of 29 patents)

5. David P Gearing (8 out of 22 patents)

6. Douglas James Hilton (6 out of 23 patents)

7. Tracy Ann Willson (5 out of 14 patents)

8. Edouard C Nice (5 out of 5 patents)

9. Julie Ann King (5 out of 5 patents)

10. Andrew W Boyd (4 out of 8 patents)

11. Leonard Charles Harrison (3 out of 12 patents)

12. Perry Francis Bartlett (3 out of 13 patents)

13. Julie A King (3 out of 3 patents)

14. Robert Frederick Seamark (3 out of 4 patents)

15. Tracey Ann Willson (3 out of 3 patents)

Core Competencies:

Immunoreactive Peptides

Leukemia Inhibitory Factor

Granulocyte-Macrophage Colony-Stimulating Factor

Neuron Development

Embryonic Stem Cells

Monoclonal Antibodies

Tumor Treatment

Functional Regeneration

Thrombocytopenia

Cytokines

Ligand Screening

Autoantigens

33 patents: Sort by Forward Citations

1. 6818217 - Immunoreactive peptides (2004-11-16),

2. 6387875 - Method of use for murine leukaemia inhibitory factor-binding protein (mLBP) (2002-05-14),

3. 6261548 - Leukaemia inhibitory factor (2001-07-17),

4. 6211352 - Method for the diagnosis and treatment of glutamic acid decarboxylase autoantigen associated diseases (2001-04-03),

5. 6184370 - Receptor-binding determinant from leukaemia inhibitory factor (2001-02-06),

6. 6177402 - Method for regulating neuron development and maintenance (2001-01-23),

7. 6136957 - Antibodies which bind granulocyte-macrophane colony-stimulating factor (2000-10-24),

8. 6093390 - Methods for promoting functional regeneration of mammalian muscle by (2000-07-25),

9. 6020306 - Receptor-type tyrosine kinase and use thereof (2000-02-01),

10. 5962321 - Leukemia inhibitory factor from mammalian species and use thereof to (1999-10-05),

11. 5891436 - Primary biliary cirrhosis autoantigen and method of use (1999-04-06),

12. 5837812 - Human islet, human brain and mouse brain glutamic acid decarboxylase GAD (1998-11-17),

13. 5750654 - Leukaemia inhibitory factor (1998-05-12),

14. 5747032 - Monoclonal antibody to human granulocyte macrophage colony stimulating (1998-05-05),

15. 5726036 - Granulocyte-macrophage colony-stimulating factor receptor and (1998-03-10),

Company Overview

Amrad Corporation Limited is an Australian biotechnology company based in Victoria, specializing in the development of innovative therapeutics and diagnostics. The organization focuses on advancing medical research, particularly in the fields of immunology and oncology, aiming to address unmet medical needs through cutting-edge technology. With a commitment to scientific excellence, Amrad collaborates with various research institutions and industry partners to enhance healthcare outcomes and contribute to the global biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

33 Patents

#2 in Victoria

#93 in Australia

#20,147 in the World

Victoria, Australia

Amrad Corporation Limited

Forward Citations = 447

48 inventors:

Nicholas Martin Gough (13 out of 15 patents)

Donald Metcalf (12 out of 21 patents)

Nicos Anthony Nicola (10 out of 23 patents)

4. Richard John Simpson (8 out of 29 patents)

5. David P Gearing (8 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amrad Corporation Limited. Retrieved from https://idiyas.com/company/amrad

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…